J
J. Apffelstaedt
Researcher at Tygerberg Hospital
Publications - 7
Citations - 1957
J. Apffelstaedt is an academic researcher from Tygerberg Hospital. The author has contributed to research in topics: Breast cancer & Zoledronic acid. The author has an hindex of 6, co-authored 7 publications receiving 1887 citations.
Papers
More filters
Journal Article
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Lee S. Rosen,David Gordon,Mary Kaminski,Anthony Howell,Andrew R. Belch,John R. Mackey,J. Apffelstaedt,Mohamed Hussein,Robert E. Coleman,Dirk J. Reitsma,John J. Seaman,Bee Lian Chen,Yvonne Ambros +12 more
TL;DR: Zoledronic acid (4 mg) via 15-minute intravenous infusion was as effective and well tolerated as 90 mg of pamidronate in the treatment of osteolytic and mixed bone metastases/lesions in patients with advanced breast cancer or multiple myeloma.
Journal ArticleDOI
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Lee S. Rosen,David Gordon,Mary Kaminski,Anthony Howell,Andrew R. Belch,John R. Mackey,J. Apffelstaedt,Mohamad A. Hussein,Robert E. Coleman,Dirk J. Reitsma,Bee-Lian Chen,John J. Seaman +11 more
TL;DR: In this article, the authors compared the long-term safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma.
Journal ArticleDOI
Prevention of Aromatase Inhibitor-Induced Bone Loss Using Risedronate: The SABRE Trial
Catherine Van Poznak,Rosemary A. Hannon,John R. Mackey,Mario Campone,J. Apffelstaedt,Glen Clack,David H. Barlow,Andreas Makris,Richard Eastell +8 more
TL;DR: In postmenopausal women at risk of fragility fracture who were receiving adjuvant anastrozole for EBC, the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favorable effects in BMD during 24 months.
Proceedings ArticleDOI
Managing cancer treatment-induced bone loss: 24-month results from the Study of Anastrozole with the Bisphosphonate RisedronatE (SABRE).
C. Van Poznak,Rosemary A. Hannon,Glen Clack,Mario Campone,John R. Mackey,J. Apffelstaedt,Richard Eastell +6 more
TL;DR: In postmenopausal women at risk for fragility fracture receiving adjuvant anastrozole for BCA, the addition of risedronate at doses established for preventing and treating osteoporosis resulted in favorable affects in BMD over 24 months.